Biological Activity
SB-3CT is a potent and competitive inhibitor of matrix metalloproteinase (MMP-2) and MMP-9.
In Vitro
SB-3CT has shown efficacy in an animal model of severe traumatic brain injury (TBI). SB-3CT inhibits MMP-9 with an inhibition constant Ki of 400±15 nM[1]. Inhibition of PC3 tumor growth by SB-3CT could also be a direct consequence of reduced extracellular matrix degradation within the bone tissue by the tumor cells themselves and/or by osteoclasts. Indeed, SB-3CT treatment is associated with a reduced osteolytic response, indicating that SB-3CT helps to preserve bone integrity[2].
In Vivo
Post-ischemic treatment with SB-3CT significantly diminishes brain damage and reduced infarct volume to about 20% of the total hemisphere. SB-3CT treatment ameliorates neurobehavioral outcomes, particularly in the motor and sensory functions[3].
References & source
Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.